Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy.
We report the case histories of 7 human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART) who had a diagnosis of Castleman disease. All 6 patients who were treated responded to chemotherapy; immune reconstitution was observed in 5 patients, but it did not prevent relapse of Castleman disease. However, the mean duration of survival observed in this series (48 months) was most probably due to immune reconstitution resulting from receipt of HAART, which reduced the mortality associated with HIV disease.
Aaron
Laurent
L
Service des Maladies Infectieuses et Tropicales, Hôpital Necker Enfants-Malades, 75743 Paris Cedex 15, France. LAAARON@wanadoo.fr
Lidove
Olivier
O
Yousry
Cherine
C
Roudiere
Laurent
L
Dupont
Bertrand
B
Viard
Jean Paul
JP
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005871:Castleman Disease / Q000209:etiology* / Q000401:mortality; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D006566:Herpesviridae Infections / Q000209:etiology* / Q000401:mortality; D019288:Herpesvirus 8, Human / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016019:Survival Analysis